12-Nov-2025 3:01 PM CST - Business Wire Kezar Life Sciences Reports Third Quarter 2025 Financial Results Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2025. In October, Kezar announced that it has been unable to align with the Food and Drug Administration (FDA) on a potential registrational clinical trial of zetomipzomib, a novel, selective inhibitor of the immunopro
13-Aug-2025 3:01 PM CST - Business Wire Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. We are on track with our clinical development and regulatory submission plan for zetomipzomib in autoimmune hepatitis, said Chris Kirk, PhD, CEO and co-founder of Keza
28-May-2025 3:01 PM CST - Business Wire Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Chris Kirk, Chief Executive Officer and Co-founder, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 2:35 pm ET in New York, NY. A webcast of the panel discussion will be available on the Even
13-May-2025 3:01 PM CST - Business Wire Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. We shared exciting results this quarter from the PORTOLA trial, the first successful randomized study in treatment-refractory AIH, said Chris Kirk, CEO and co-founder
12-Nov-2024 3:01 PM CST - Business Wire Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a business update. The team at Kezar has made great progress towards completing the double-blind portion of the PORTOLA trial as we prepare for a data release in first half of 2025,
17-Oct-2024 7:35 AM CST - Business Wire Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that its Board of Directors (the Board) has unanimously rejected the previously disclosed unsolicited, non-binding proposal from Concentra Biosciences, LLC (Concentra) to acquire all of the outstanding shares of common stock of Kezar for cash consideration o
12-Nov-2025 3:01 PM CST - Business Wire Kezar Life Sciences Reports Third Quarter 2025 Financial Results Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2025. In October, Kezar announced that it has been unable to align with the Food and Drug Administration (FDA) on a potential registrational clinical trial of zetomipzomib, a novel, selective inhibitor of the immunopro
13-Aug-2025 3:01 PM CST - Business Wire Kezar Life Sciences Reports Second Quarter 2025 Financial Results and Provides Business Update Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the second quarter ended June 30, 2025, and provided a business update. We are on track with our clinical development and regulatory submission plan for zetomipzomib in autoimmune hepatitis, said Chris Kirk, PhD, CEO and co-founder of Keza
28-May-2025 3:01 PM CST - Business Wire Kezar Life Sciences to Participate in the Jefferies Global Healthcare Conference Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that Chris Kirk, Chief Executive Officer and Co-founder, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 2:35 pm ET in New York, NY. A webcast of the panel discussion will be available on the Even
13-May-2025 3:01 PM CST - Business Wire Kezar Life Sciences Reports First Quarter 2025 Financial Results and Provides Business Update Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the first quarter ended March 31, 2025, and provided a business update. We shared exciting results this quarter from the PORTOLA trial, the first successful randomized study in treatment-refractory AIH, said Chris Kirk, CEO and co-founder
12-Nov-2024 3:01 PM CST - Business Wire Kezar Life Sciences Reports Third Quarter 2024 Financial Results and Provides Business Update Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a business update. The team at Kezar has made great progress towards completing the double-blind portion of the PORTOLA trial as we prepare for a data release in first half of 2025,
17-Oct-2024 7:35 AM CST - Business Wire Kezar Board Unanimously Rejects Unsolicited Concentra Proposal and Adopts Limited Duration Stockholder Rights Plan Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that its Board of Directors (the Board) has unanimously rejected the previously disclosed unsolicited, non-binding proposal from Concentra Biosciences, LLC (Concentra) to acquire all of the outstanding shares of common stock of Kezar for cash consideration o
